Published in Anticancer Res on September 17, 1992
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A (2001) 7.51
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci U S A (2005) 1.78
Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol (2008) 1.49
Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics. J Histochem Cytochem (2006) 1.45
Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A (2003) 1.41
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A (2002) 1.38
Multi-class cancer classification by total principal component regression (TPCR) using microarray gene expression data. Nucleic Acids Res (2005) 1.19
HLA class I and II genotype of the NCI-60 cell lines. J Transl Med (2005) 1.11
A multivariate approach to the integration of multi-omics datasets. BMC Bioinformatics (2014) 1.01
Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther (2010) 0.97
Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A (2005) 0.93
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
Characterization of liposarcoma cell lines for preclinical and biological studies. Sarcoma (2012) 0.90
Standardized high-throughput evaluation of cell-based compound screens. BMC Bioinformatics (2008) 0.85
Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol (2009) 0.84
Engineered reversal of drug resistance in cancer cells--metastases suppressor factors as change agents. Nucleic Acids Res (2013) 0.83
DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ (2015) 0.83
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
Systematic analyses of the cytotoxic effects of compound 11a, a putative synthetic agonist of photoreceptor-specific nuclear receptor (PNR), in cancer cell lines. PLoS One (2013) 0.81
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One (2012) 0.80
MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis. Invest New Drugs (2010) 0.78
SBMLmod: a Python-based web application and web service for efficient data integration and model simulation. BMC Bioinformatics (2017) 0.75
A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob DNA (2016) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Bacterial community structures of phosphate-removing and non-phosphate-removing activated sludges from sequencing batch reactors. Appl Environ Microbiol (1995) 11.83
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
Directed tagging of the Arabidopsis FATTY ACID ELONGATION1 (FAE1) gene with the maize transposon activator. Plant Cell (1995) 4.15
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst (1990) 4.08
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Procedures for the purification of interleukin 3 to homogeneity. J Immunol (1982) 3.96
Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology (2001) 3.38
A clinician's guide for conducting randomized trials in individual patients. CMAJ (1988) 3.35
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A (1996) 3.13
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
Identification of polyphosphate-accumulating organisms and design of 16S rRNA-directed probes for their detection and quantitation. Appl Environ Microbiol (2000) 2.57
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol (1990) 2.49
An index of scientific quality for health reports in the lay press. J Clin Epidemiol (1993) 2.47
N of 1 randomized trials for investigating new drugs. Control Clin Trials (1990) 2.37
JC virus enhancer-promoter active in human brain cells. Science (1984) 2.36
Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol (1989) 2.33
In vivo cultivation of tumor cells in hollow fibers. Life Sci (1995) 2.29
Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol (1998) 2.19
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother (1987) 2.11
Effects of prehospital care on outcome in patients with cardiac illness. Ann Emerg Med (1995) 2.09
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol (2001) 2.07
Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res (1991) 2.06
Catalysis research of relevance to carbon management: progress, challenges, and opportunities. Chem Rev (2001) 1.99
Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J Med Chem (1995) 1.98
Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res (1988) 1.95
The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem (1992) 1.89
Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases. Am J Surg Pathol (1998) 1.86
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol (2000) 1.77
Women living with HIV: disclosure, violence, and social support. J Urban Health (2000) 1.69
Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol (1992) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Phenotypic characteristics of cell lines requiring interleukin 3 for growth. J Immunol (1982) 1.67
Microbiology of a nitrite-oxidizing bioreactor. Appl Environ Microbiol (1998) 1.67
The structure of the glycopeptide of human gamma G myeloma proteins. J Biol Chem (1971) 1.63
Identification of some of the major groups of bacteria in efficient and nonefficient biological phosphorus removal activated sludge systems. Appl Environ Microbiol (1999) 1.62
Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas. J Vasc Interv Radiol (1999) 1.58
Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol (1999) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Cytotoxic geranyl stilbenes from Macaranga schweinfurthii. J Nat Prod (1998) 1.50
Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur J Cancer (1990) 1.49
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother (1989) 1.48
Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des (1995) 1.46
[Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z Gastroenterol (2011) 1.46
The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl (2004) 1.45
Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. J Virol (1996) 1.44
The IWA Anaerobic Digestion Model No 1 (ADM1). Water Sci Technol (2002) 1.44
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2000) 1.43
Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer (2001) 1.42
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol (1999) 1.41
Evidence for the Clara cell as a site of cytochrome P450-dependent mixed-function oxidase activity in lung. Nature (1977) 1.41
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1993) 1.41
Intradermal and subcutaneous leiomyosarcoma: a clinicopathological and immunohistochemical study of 41 cases. J Cutan Pathol (1996) 1.40
McDonald cerclage under pudendal nerve block. Am J Obstet Gynecol (1993) 1.40
Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med (1989) 1.35
Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res (1987) 1.34
Phenotypes of murine leukemia virus-induced tumors: influence of 3' viral coding sequences. J Virol (1992) 1.33
Interleukin 3: possible roles in the regulation of lymphocyte differentiation and growth. Immunol Rev (1982) 1.33
Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem (1991) 1.32
Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol (2001) 1.31
Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res (1988) 1.29
Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs (1995) 1.29
Studies of blood pressure in Tecumseh, Michigan. I. Blood pressure in young people and its relationship to personal and familial characteristics and complications of pregnancy in mothers. Am J Epidemiol (1980) 1.28
Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther (2001) 1.28
RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J Virol (1994) 1.27
Familial occurrence of chronic respiratory disease and familial resemblance in ventilatory capacity. J Chronic Dis (1975) 1.27
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol (2001) 1.27
Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod (1993) 1.26
Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol (1991) 1.26
Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res (1997) 1.26
Crystal structure of Escherichia coli HdeA. Nat Struct Biol (1998) 1.25
Modifications to Rives technique for midline incisional hernia repair. Hernia (2001) 1.25
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A (1991) 1.24
Accuracy of sphygmomanometers in hospital practice. Arch Intern Med (1970) 1.23
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem (1998) 1.23
Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol (1996) 1.21
A semiautomated multiparameter approach for anti-HIV drug screening. J Virol Methods (1991) 1.21
The Caenorhabditis elegans SH2 domain-containing protein tyrosine phosphatase PTP-2 participates in signal transduction during oogenesis and vulval development. Genes Dev (1998) 1.21
Infection of immune mast cells by Harvey sarcoma virus: immortalization without loss of requirement for interleukin-3. Mol Cell Biol (1985) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
HIV inhibitory natural products. 26. Quinoline alkaloids from Euodia roxburghiana. J Nat Prod (1996) 1.19
Identification and characterization of novel low-temperature-inducible promoters of Escherichia coli. J Bacteriol (1992) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
HIV-inhibitory cembrane derivatives from a Philippines collection of the soft coral Lobophytum species. J Nat Prod (2000) 1.18
Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat, and oxygen. Am Rev Respir Dis (1979) 1.18
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother (1996) 1.17
The 6-O-methylglucose-containing lipopolysaccharide of Mycobacterium phlei. Identification of the lipid components. J Biol Chem (1968) 1.16